Global Search | Novartis

Sort by

Relevance

Newest first

Oldest first

Hide Filters

Showing 2830 results

Clinical Trials / Feb 20, 2026

A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)
Clinical Trials / Mar 11, 2026

Secukinumab Open Label Roll-over Extension Protocol
Clinical Trials / Apr 06, 2026

Safety and Efficacy Study of Fingolimod in Taiwanese Adults (≥ 20years) With Relapsing Remitting Multiple Sclerosis
Clinical Trials / May 05, 2026

24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up
Clinical Trials / Mar 18, 2026

Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis
Clinical Trials / Jan 31, 2025

Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)
Clinical Trials / May 16, 2024

Post-Authorization Safety Study for Assessment of Pregnancy Outcomes in Patients Treated With Mayzent
Press release / Feb 24, 2026

New real‑world data reinforce earlier use of Pluvicto™ before chemotherapy in metastatic castration-resistant prostate cancer

In the real-world, Pluvicto™ showed 13.5 months median PFS in chemo-naïve patients with PSMA-positive mCRPCReal‑world evidence showed Pluvicto achieved longer PFS when initiated after one ARPI…
Press release / Feb 23, 2026

Novartis presents Rhapsido® (remibrutinib) data at AAAAI, showing potential beyond chronic spontaneous urticaria (CSU)

Analyses from REMIX-1 & -2 studies on CSU disease control and early symptom relief will be presented Phase II data evaluating safety and efficacy results of remibrutinib for treatment of peanut…
Press release / Dec 09, 2025

Novartis ianalumab significantly extends disease control in patients with immune thrombocytopenia with only four once-monthly doses

Ianalumab (9 mg/kg) plus eltrombopag extended ITP disease control by 45% with patients maintaining disease control 2.8 times longer than with placebo plus eltrombopag1,2 62% of patients treated with…

‹ Previous page
1
…
15
16
17
18
19
20
21
…
283
› Next page